Rubius Therapeutics Stock

Rubius Therapeutics ROA 2024

Rubius Therapeutics ROA

-7.78

Ticker

RUBY

ISIN

US78116T1034

WKN

A2JQ3H

In 2024, Rubius Therapeutics's return on assets (ROA) was -7.78, a 1,158.4% increase from the -0.62 ROA in the previous year.

Rubius Therapeutics Aktienanalyse

What does Rubius Therapeutics do?

Rubius Therapeutics Inc is a US biotechnology company founded in 2013. The company's goal is to develop therapies based on artificially manufactured red blood cells, known as RBCs, to treat diseases for which effective treatment methods are currently unavailable. The idea for the creation of Rubius began with a discovery by Dr. Aviv Regev at the Broad Institute, a research institute in Cambridge, Massachusetts. She discovered a method for using artificially manufactured red blood cells to treat diseases. Rubius was launched to intensify research and development in this area and create groundbreaking therapies using a new technology. Rubius has a unique business model. The company relies on a novel development platform that focuses not on delivering drugs into cells, but on using red blood cells as a base. The technology enables the incorporation of special proteins or active ingredients into the RBCs' membrane. By selectively releasing these active ingredients into the bloodstream, diseases can be directly treated at their source. This approach offers many advantages, such as increased effectiveness and reduced side effects. Rubius is currently working on several product candidates in various clinical research programs. The company has three main areas of focus: immunology, rare diseases, and cancer. In the field of immunology, they are developing therapies for autoimmune diseases such as rheumatoid arthritis or multiple sclerosis. The company also has a pipeline of products that can be used for rare blood disorders like hemophilia. Additionally, Rubius is involved in cancer immunotherapy, aiming to combat cancer cells by targeted activation of the immune system. Rubius Therapeutics has already achieved successes, such as the approval of an RBC-based drug for sickle cell disease by the US Food and Drug Administration (FDA) in spring 2020. The first target molecule on the RBC surface refers to the C5b9 membrane attack complex, which can cause damage to red blood cells, inflammation, and damage to blood vessels. Rubius aims to incorporate a specific protein into the artificial red blood cells that blocks the attack on red blood cells by the C5b9 membrane attack complex. As a leader in the biotechnology industry, Rubius is an innovative company with a novel business model and promising technology. It is shaping the industry with various developments and revolutionizing therapy for serious diseases that previously lacked satisfactory treatment methods. Overall, Rubius is a promising company with great potential for the future. Rubius Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Rubius Therapeutics's Return on Assets (ROA)

Rubius Therapeutics's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Rubius Therapeutics's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Rubius Therapeutics's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Rubius Therapeutics’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Rubius Therapeutics stock

What is the Return on Assets (ROA) of Rubius Therapeutics this year?

The Return on Assets (ROA) of Rubius Therapeutics is -7.78 undefined this year.

What was the ROA of Rubius Therapeutics compared to the previous year?

The ROA of Rubius Therapeutics has increased by 1,158.4% compared to the previous year.

What consequences do high ROA have for investors of Rubius Therapeutics?

A high ROA is advantageous for investors of Rubius Therapeutics, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Rubius Therapeutics?

A low ROA can be unfavorable for investors of Rubius Therapeutics as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Rubius Therapeutics affect the company?

An increase in ROA of Rubius Therapeutics can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Rubius Therapeutics impact the company?

A reduction in the ROA of Rubius Therapeutics can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Rubius Therapeutics?

Some factors that can influence the ROA of Rubius Therapeutics include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Rubius Therapeutics important for investors?

The ROA of Rubius Therapeutics is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Rubius Therapeutics take to improve ROA?

To improve ROA, Rubius Therapeutics can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Rubius Therapeutics pay?

Over the past 12 months, Rubius Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Rubius Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Rubius Therapeutics?

The current dividend yield of Rubius Therapeutics is .

When does Rubius Therapeutics pay dividends?

Rubius Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Rubius Therapeutics?

Rubius Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Rubius Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Rubius Therapeutics located?

Rubius Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Rubius Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Rubius Therapeutics from 12/29/2023 amounting to 0.058 USD, you needed to have the stock in your portfolio before the ex-date on 1/2/2024.

When did Rubius Therapeutics pay the last dividend?

The last dividend was paid out on 12/29/2023.

What was the dividend of Rubius Therapeutics in the year 2023?

In the year 2023, Rubius Therapeutics distributed 0 USD as dividends.

In which currency does Rubius Therapeutics pay out the dividend?

The dividends of Rubius Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Rubius Therapeutics

Our stock analysis for Rubius Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Rubius Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.